Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1370317 | Bioorganic & Medicinal Chemistry Letters | 2013 | 4 Pages |
Abstract
We report here the discovery of a novel series of selective mTOR kinase inhibitors and the identification of CC214-2, a compound with demonstrated anti-tumor activity upon oral dosing in a PC3 prostate cancer xenograft model. A series of 4,6-disubstituted-3,4-dihydropyrazino[2,3-b]pyrazine-2(1H)-ones were discovered through a core modification of our original compound series. Analogs from this series have excellent mTOR potency and maintain selectivity over the related PI3Kα lipid kinase. Compounds such as CC214-2 were found to block both mTORC1(pS6) and mTORC2(pAktS473) signaling in PC3 cancer cells, in vitro and in vivo.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Deborah S. Mortensen, John Sapienza, Branden G.S. Lee, Sophie M. Perrin-Ninkovic, Roy Harris, Graziella Shevlin, Jason S. Parnes, Brandon Whitefield, Matt Hickman, Gody Khambatta, Rene R. Bisonette, Sophie Peng, Jim C. Gamez, Jim Leisten,